Simonetta Mocci

5.6k total citations
61 papers, 2.4k citations indexed

About

Simonetta Mocci is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Simonetta Mocci has authored 61 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Simonetta Mocci's work include Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Genomics and Diagnostics (14 papers). Simonetta Mocci is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Genomics and Diagnostics (14 papers). Simonetta Mocci collaborates with scholars based in United States, Italy and Poland. Simonetta Mocci's co-authors include Paolo Puccetti, Robert L. Coffman, E. Richard Stanley, Francesco Bistoni, Luigina Romani, Jeffrey W. Pollard, Melissa G. Dominguez, Willy Hofstetter, Orin Chisholm and Marco Cecchini and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Simonetta Mocci

61 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simonetta Mocci United States	22	995	970	679	379	301	61	2.4k
Toshiki Yajima Japan	31	1.2k 1.2×	620 0.6×	423 0.6×	596 1.6×	107 0.4×	111	2.6k
Anke Franzke Germany	29	1.3k 1.3×	908 0.9×	310 0.5×	737 1.9×	147 0.5×	65	2.8k
Katie Streicher United States	26	676 0.7×	604 0.6×	375 0.6×	668 1.8×	189 0.6×	62	2.4k
Christian Koenecke Germany	29	1.2k 1.2×	718 0.7×	129 0.2×	395 1.0×	201 0.7×	108	2.5k
Liang Duan China	22	460 0.5×	400 0.4×	466 0.7×	749 2.0×	105 0.3×	74	1.7k
Tetsuya Eto Japan	34	1.1k 1.1×	886 0.9×	256 0.4×	566 1.5×	130 0.4×	263	3.9k
Takeshi Shimaoka Japan	28	1.9k 1.9×	976 1.0×	169 0.2×	535 1.4×	115 0.4×	31	2.7k
G J Mufti United Kingdom	36	1.0k 1.0×	1.4k 1.5×	283 0.4×	1.2k 3.3×	164 0.5×	119	4.8k
Bertrand Routy Canada	23	777 0.8×	1.9k 2.0×	538 0.8×	1.5k 3.9×	457 1.5×	56	3.2k
Yong‐Soo Bae South Korea	28	1.0k 1.0×	558 0.6×	142 0.2×	742 2.0×	172 0.6×	76	2.1k

Countries citing papers authored by Simonetta Mocci

Since Specialization

Citations

This map shows the geographic impact of Simonetta Mocci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simonetta Mocci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simonetta Mocci more than expected).

Fields of papers citing papers by Simonetta Mocci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simonetta Mocci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simonetta Mocci. The network helps show where Simonetta Mocci may publish in the future.

Co-authorship network of co-authors of Simonetta Mocci

This figure shows the co-authorship network connecting the top 25 collaborators of Simonetta Mocci. A scholar is included among the top collaborators of Simonetta Mocci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simonetta Mocci. Simonetta Mocci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

An, Jusheng, Guiling Li, Jennifer Zhang, et al.. (2025). Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907). Gynecologic Oncology. 202. 33–40. 1 indexed citations

Corr, Bradley R., Ecaterina E. Dumbrava, Alexander I. Spira, et al.. (2024). 733P Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03. Annals of Oncology. 35. S558–S558. 1 indexed citations

Noé, Johannes, Walter Bordogna, Venice Archer, et al.. (2022). Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC. JTO Clinical and Research Reports. 3(7). 100341–100341. 5 indexed citations

Patil, Namrata S., Wei Zou, Simonetta Mocci, et al.. (2021). C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients. PLoS ONE. 16(2). e0246486–e0246486. 7 indexed citations

Jassem, Jacek, Filippo de Marinis, Giuseppe Giaccone, et al.. (2021). Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC. Journal of Thoracic Oncology. 16(11). 1872–1882. 114 indexed citations

Paul, Soumen, Simonetta Mocci, Zoe J. Assaf, et al.. (2020). 1301P Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses. Annals of Oncology. 31. S841–S841. 1 indexed citations

Spigel, David R., Martin J. Edelman, Kenneth J. O’Byrne, et al.. (2017). Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung. Journal of Clinical Oncology. 35(4). 412–420. 232 indexed citations

Spigel, David R., Martin J. Edelman, Kenneth J. O’Byrne, et al.. (2017). Results from the phase iii randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage iiib or iv non–small-cell lung cancer: METLung. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas). 1 indexed citations

Mok, Tony, Shirish M. Gadgeel, Vamsidhar Velcheti, et al.. (2017). Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC. Annals of Oncology. 28. v494–v495. 12 indexed citations

10.

Peters, Solange, Enric Carcereny, Marina Chiara Garassino, et al.. (2017). Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial. Annals of Oncology. 28. ii29–ii30. 2 indexed citations

11.

Garassino, Marina Chiara, Naiyer A. Rizvi, Benjamin Besse, et al.. (2017). OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study. Journal of Thoracic Oncology. 12(1). S251–S252. 13 indexed citations

12.

Jassem, Jacek, Filippo de Marinis, David R. Spigel, et al.. (2017). IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC. Annals of Oncology. 28. ii50–ii50. 3 indexed citations

13.

Cappuzzo, Federico, Martin Reck, Vassiliki A. Papadimitrakopoulou, et al.. (2017). P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program. Journal of Thoracic Oncology. 12(1). S1296–S1297. 1 indexed citations

14.

Kowanetz, Marcin, Wei Zou, David S. Shames, et al.. (2016). Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC. Annals of Oncology. 27. vi23–vi23. 34 indexed citations

15.

Jotte, Robert M., Mark A. Socinski, Martin Reck, et al.. (2016). PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program. Journal of Thoracic Oncology. 11(11). S302–S303. 4 indexed citations

16.

Herbst, Roy S., Filippo de Marinis, Jacek Jassem, et al.. (2015). 355TiP Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC. Annals of Oncology. 26. ix103–ix103. 3 indexed citations

17.

Borin, Marie T., et al.. (2014). Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer. Cancer Chemotherapy and Pharmacology. 75(2). 401–410. 5 indexed citations

18.

Coffman, RL, Simonetta Mocci, & Anne O’Garra. (1999). The Stability and Reversibility of Th1 and Th2 Populations. Current topics in microbiology and immunology. 238. 1–12. 52 indexed citations

19.

Pollard, Jeffrey W., Melissa G. Dominguez, Simonetta Mocci, Paula E. Cohen, & E. Richard Stanley. (1997). Effect of the Colony-Stimulating Factor-1 Null Mutation, Osteopetrotic (csfmoP), on the Distribution of Macrophages in the Male Mouse Reproductive Tract1. Biology of Reproduction. 56(5). 1290–1300. 43 indexed citations

20.

Romani, Luigina, Simonetta Mocci, Elio Cenci, et al.. (1992). Immunoregulatory role of different t cell subsets in murine candidiasis. Pharmacological Research. 26. 200–201. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact